Stock AnalizFresenius Medical Care AG FMS
Misc Health and Biotechnology Services · data as of November 13, 2026
Fresenius Medical Care AG (FMS) is a healthcare company listed in the US with a market value of about $12.3B. In the twelve months to September 30, 2026 it had revenue of $21.5B and net income of $907M, a net margin of 4.2%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is value (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 13.3, a price to free cash flow of 6.2, 5-year revenue growth of 1% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 65% above the current price.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- Profit margin improving
- Profitable 5 years in a row
- Positive free cash flow
Checks not passed
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.5B | $23.1B | $20.1B | $21.5B | $20.7B | $20.0B | $21.9B | $19.6B | $18.9B | $21.3B | $17.9B |
| Net income | $907M | $1.1B | $559M | $551M | $718M | $1.1B | $1.4B | $1.3B | $2.3B | $1.5B | $1.2B |
| Free cash flow | $2.0B | — | — | — | — | — | — | $1.6B | $1.2B | $1.5B | $1.1B |
| EPS (diluted) | $1.66 | $2.06 | $1.00 | $0.99 | $1.29 | $1.97 | $2.56 | $2.41 | $4.06 | $2.75 | $2.23 |
| Net margin | 4.2% | 5.0% | 2.8% | 2.6% | 3.5% | 5.5% | 6.5% | 6.9% | 12.0% | 7.2% | 6.9% |
| ROIC | — | 6.0% | 3.8% | 3.8% | 4.1% | 5.5% | 7.2% | 6.9% | 12.8% | 11.1% | 9.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Fresenius Medical Care’s P/E ratio?
About 13.3, based on the last twelve months of diluted earnings per share (forward P/E about 8.2).
Is Fresenius Medical Care stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 65% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Fresenius Medical Care pay a dividend?
Yes. The dividend yield is about 3.96%, and it has paid dividends for 9 years in our data.
Is Fresenius Medical Care a good stock to buy?
We do not give buy or sell advice. Fresenius Medical Care scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.